Ki16425, a Subtype-Selective Antagonist for EDG-Family Lysophosphatidic Acid Receptors

HIDEO OHTA, KOICHI SATO, NA横 Murata, ALATANGAOLE DAMIRIN, ENKHZOL MALCHINKHUU, JUNKO KON, TAKAO KIMURA, MASAYUKI TOBO, YUJI Yamazaki, TOMOKO Watanabe, MIKIO Yagi, Motoko SatO, RIKA Suzuki, HIDEKO MUROOKA, TERUYUKI SAKAI, TSUYOSHI Nishitoba, Dong-Soon Im, HIROMI NOCHI, KOICHI TAMOTO, HIDEAKI TOT apura, and FUMIKAZU OAKAJIMA

Pharmaceutical Research Laboratory, Kirin Brewery Co., Gunma, Japan (H.O., Y.Y., T.W., M.Y., M.S., R.S., H.M., T.S., T.N.); Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Japan (K.S., N.M., A.D., E.M., J.K., T.K., M.T., H.T., F.O.); Laboratory of Pharmacology, College of Pharmacy, Pusan National University, Busan, Republic of Korea (D.I.); and Department of Microbiology, Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan (H.N., K.T.)

Received December 16, 2002; accepted July 16, 2003

ABSTRACT

Lysophosphatidic acid (LPA) exerts a variety of biological responses through specific receptors: three subtypes of the EDG-family receptors, LPA1, LPA2, and LPA3 (formerly known as EDG-2, EDG-4, and EDG-7, respectively), and LPA4/GPR23, structurally distinct from the EDG-family receptors, have so far been identified. In the present study, we characterized the action mechanisms of 3-[4-[(1-[2-chlorophenyl]ethoxy)carbonyl amino]-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid (Ki16425) on the EDG-family LPA receptors. Ki16425 inhibited several responses specific to LPA, depending on the cell types, without any appreciable effect on the responses to other related lipid receptor agonists, including sphingosine 1-phosphate. With the cells overexpressing LPA1, LPA2, or LPA3, we examined the selectivity and mode of inhibition by Ki16425 against the LPA-induced actions and compared them with those of dioctyl glycerol pyrophosphate (DGPP 8:0), a recently identified antagonist for LPA receptors. Ki16425 inhibited the LPA-induced response in the decreasing order of LPA1 > LPA3 > LPA2, whereas DGPP 8:0 preferentially inhibited the LPA3-induced actions. Ki16425 inhibited LPA-induced guanosine 5’-O-(3-thiotriophosphate binding as well as LPA receptor binding to membrane fractions with a same pharmacological specificity as in intact cells. The difference in the inhibition profile of Ki16425 and DGPP 8:0 was exploited for the evaluation of receptor subtypes involved in responses to LPA in A431 cells. Finally, Ki16425 also inhibited LPA-induced long-term responses, including DNA synthesis and cell migration. In conclusion, Ki16425 selectively inhibits LPA receptor-mediated actions, especially through LPA1 and LPA3; therefore, it may be useful in evaluating the role of LPA and its receptor subtypes involved in biological actions.

This work was supported in part by a research grant grants-in-aid for scientific research from the Japan Society for the Promotion of Science and by research grants from The Mitsubishi Foundation, Pusan National University and Yamamoto Foundation for Research on Metabolic Disorders. H.O. and K.S. contributed equally to this work.

ABBREVIATIONS: LPA, 1-oleoyl-sn-glycero-3-phosphate or lysophosphatidic acid; Ki16425, 3-[4-[(1-[2-chlorophenyl]ethoxy)carbonyl amino]-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid; DGPP 8:0, dioctyl glycerol pyrophosphate; PAF, platelet activating factor; S1P, sphingosine 1-phosphate; SPC, sphingosylphosphorylcholine; EDG, endothelial differentiation gene; BSA, bovine serum albumin; AM, acetoxymethyl ester; PTX, pertussis toxin; GTPyS, guanosine 5’-O-(3-thiotriophosphate; BP, base pair(s); RT, reverse transcription; PCR, polymerase chain reaction; CHO, Chinese hamster ovary; HEK, human embryonic kidney; FBS, fetal bovine serum; Ro 20-1724, 4-[3-butoxy-4-methoxyphenyl]-2-imidazolidinone; MOPS, 3-(N-morpholino)propanesulfonic acid; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; VPC12249, N-oleoyl-2-(benzyl-4-oxybenzyl) ethanolamide phosphoric acid.
Receptor antagonists are very useful tools for evaluating the role of LPA and its receptors in biological actions and for controlling specific diseases (Tigyi, 2001). Based on their ability to inhibit Ca^{2+} response to LPA in A431 cells or LPA-responsive cells, we have screened 150,000 low-molecular-weight compounds developed by the Kirin Brewery Co. Ltd, for LPA receptor antagonists, and found that some isoxazole derivatives showed such an inhibitory activity against the LPA action. We therefore synthesized several isoxazole derivatives and finally selected Ki16425 as the best candidate compound (Ueno et al., 2001). In the present study, we examined the pharmacological properties of Ki16425 and compared it with that of DGPP 8:0, a recently identified LPA antagonist (Fischer et al., 2001). We found that Ki16425 inhibited LPA-induced actions in a manner highly specific to LPA and LPA receptor subtypes. Such differences in the selectivity of Ki16425 and DGPP 8:0 were successfully applied to discriminate the receptor subtypes in A431 cells. Thus, the novel antagonist Ki16425 seems to be a useful tool for investigating physiological and pathophysiological roles of LPA and its receptors.

Materials and Methods

Materials. 1-Oleoyl-sn-glycero-3-phosphate (LPA), 1,2-diacyl-sn-glycero-3-phosphorylcholine palmitoyl (PAF), and 1-O-alkyl (PAF), and 1-β-D-galactosylsphingosine (psychosine) were purchased from Sigma-Aldrich (St. Louis, MO); sphingosine 1-phosphate (SIP) was from Cayman Chemical Co. (Ann Arbor, MI); sphingosylphosphorylcholine (SPC) was from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA); 2-arachidonylglycerol and fatty acid-free BSA (Fraction V) were from Calbiochem-Novabiochem Co. (San Diego, CA); dioctyl glycercophosphate (DGPP 8:0) was from Avanti Polar Lipids, Inc. (Alabaster, AL); Fura 2/AM was from Dojindo (Tokyo, Japan); PTX was from List Biological Laboratories, Inc. (Campbell, CA); [3H]myo-inositol (23.0 Ci/mmol) was from American Radiolabeled Chemicals, Inc. (St. Louis, MO); [3H]GTPyS (1.200 Ci/mmol) was from Amersham Biosciences, Inc. (Piscataway, NJ); and [3H]LPA (48 Ci/mmol) was from PerkinElmer Life Science Products, Inc. (Boston, MA). Ki16425 was synthesized by the Kirin Brewery Co. (Takasaki, Japan), and its chemical structure is shown in Fig. 1.

Preparation of LPA Receptor cDNA Plasmids and Expression. The entire coding regions of LPA1 (1,095 bp, GenBank accession number Y09479), LPA2 (1,149 bp, GenBank accession number AF011466), and LPA3 (1,148 bp, GenBank accession number AF127138) were amplified from human cDNA library by RT-PCR. The respective amplified fragment was subcloned into the EcoRI site of pEFneo eukaryotic expression vector (Kon et al., 1999; Sato et al., 2000), and each DNA sequence was confirmed. The primers used for the RT-PCR were as follows. The 5’-primers contained an EcoRI site, a Kozak sequence (CCACC), and the N-terminal region of the respective receptor. The 3’-primers contained an EcoRI site and a stop codon in addition to the C-terminal region of the respective receptor. CHO cells or RH7777 cells were transfected with pEFneo empty vector alone or the pEFneo vector containing human LPA1, human LPA2, or human LPA3 by electroporation, and the neomycin-resistant cells (G418 sulfate at 1 mg/ml for CHO cells and 0.3 mg/ml for RH7777 cells) were selected. CHO cells resistant to G-418 were used in bulk, whereas RH7777 cells expressing the different LPA receptor subtypes were cloned by limiting dilution. Subsequently, clonal RH7777 cells expressing human LPA1 (C3) and human LPA3 (C5) were isolated. However, in the early stages of the experiments, we were unable to obtain stable human LPA2, RH7777 cells; therefore, we used a stable mouse LPA1-expressing clone of RH7777 cells, which was provided by Prof. Kevin R. Lynch of the University of Virginia School of Medicine (Im et al., 2000). Human LPA1 cDNA was also subcloned into the HindIII/BamHI site of pcDNA3. Human and mouse orthologs of LPA1 subcloned into pcDNA3 vector (Im et al., 2000), provided by Prof. Kevin R. Lynch, were transfected into HEK293T cells.

Cell Culture. THP-1, HL-60, and A431 cells were cultured in RPMI 1640 media supplemented with 10% (v/v) FBS (Sigma) (Okajima and Kondo, 1995); Swiss 3T3 fibroblasts, SIP receptor-transfected CHO cells (Kon et al., 1999), and LPA receptor-transfected CHO cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) FBS; and LPA receptor-transfected RH7777 cells and HEK293T cells were cultured in minimum essential medium supplemented with 10% (v/v) FBS. FRTL-5 thyroid cells and PC-12 cells were cultured as described previously (Sho et al., 1999; Maschberger et al., 2000), and has also been identified as a growth-promoting factor for cancer cells in malignant ascites of patients suffering from ovarian cancer (Xu et al., 1995; Xu et al., 2001). These cellular responses to LPA are mediated through G-protein-coupled receptors, and several subtypes of LPA receptors, including LPA1/EDG-2, LPA2/EDG-4, LPA3/EDG-7, and LPA4/GPR23, a non-EDG-family LPA receptor, have been identified (Hecht et al., 1996; An et al., 1998a,b; Bandoh et al., 1999; Moolenaar, 1999; Contos et al., 2000; Im et al., 2000; Ye et al., 2002; Noguchi et al., 2003), although a novel intracellular mechanism through peroxisome proliferator-activated receptor γ was recently demonstrated (McIntyre et al., 2003). These LPA receptor subtypes are expressed and function in a variety of cell types; however, the precise role of each LPA receptor subtype has not yet been fully characterized.

![Fig. 1. Chemical structure of Ki16425.](image)
membranes were prepared as described previously (Kon et al., 1999). In some experiments, the medium was changed to fresh minimum essential medium supplemented with plasmid DNA (6 μg) and binding activity was measured as for GTPγS binding assay. Nonspecific binding was determined in the presence of 10 μM unlabeled LPA.

RNA Extraction and Northern Blot Analysis. Total RNA was prepared from the cells using TRIzol (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Total RNA (20 μg) was electrophoresed on a 1% agarose gel containing 3.7% formaldehyde and transferred to a nitrocellulose membrane. The membranes were then hybridized with 32P-labeled probes. The blots were washed at 60°C and exposed to X-ray films. Genes were amplified by RT-PCR using the same RNA samples. Degenerate DNA primers were based on the cDNA sequences of the human LPA1 (GenBank accession number Y09479), human LPA2 (GenBank accession number AF011466), and human LPA3 (GenBank accession number AF011466). The resulting PCR products were cloned into pBluescript KS (Stratagene, La Jolla, CA) and sequenced.

1991; Sato et al., 1997). For cAMP assay, RH7777 cells were plated to dishes coated with rat tail collagen (400 μg/ml). Twenty-four hours before experiments, the medium was replaced with serum-free medium as specified containing 0.1% (w/v) BSA (fraction V) and 10 μM Ki6425. As for GTPγS binding and [3H]LPA binding assays, each receptor plasmid DNA (6 μg) encoding mouse LPA1, human LPA2, human LPA3, or human LPA4 was mixed with plasmids encoding the C532G rat mutant of Gα25 (6 μg), bovine β1(6 μg), and γ2 subunits (6 μg) (Tomura et al., 1997), and transfected into HEK293T cells using calcium phosphate precipitate method (Im et al., 2000). After 24 h, the medium was changed to fresh minimum essential medium supplemented with 10% (v/v) FBS and cells were cultured for an additional 24 h. The cells were then washed once and preincubated for 10 min at 37°C in HEPES-buffered medium. The cAMP concentration was then measured as described previously (Sho et al., 1991).

Measurements of [Ca2+]i. THP-1 and HL-60 cells were harvested by centrifugation (250g). RH7777 cells transfected with LPA receptors were washed with Ca2+- and Mg2+-free phosphate-buffered saline containing 4 mM EGTA at 37°C for 5–10 min and then harvested. Other cells were harvested with trypsin (0.05%) after washing with Ca2+- and Mg2+-free phosphate-buffered saline containing 4 mM EGTA. The cells were centrifuged at 250g, and pelleted cells were resuspended in Ham’s medium containing 10% FBS and incubated with 1 μM Fura 2/AM for 20 min. The cells were washed twice and resuspended in the HEPES-buffered medium. The HEPES-buffered medium was composed of 20 mM HEPES, pH 7.4, 134 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2 mM CaCl2, 2.5 mM NaHCO3, 5 mM glucose, and 0.1% (w/v) BSA (fraction V). [Ca2+]i was estimated from the change in the fluorescence of the Fura 2-loaded cells, as described previously (Oka-jima et al., 1998; Kon et al., 1999). Unless otherwise stated, the cells were incubated for 1 min in the presence or absence of Ki6425 or DGPP 8:0, and indicated agonists were added to the incubation medium to monitor [Ca2+]i. The net [Ca2+]i change (peak value – basal value) at around 15 s was calculated.

**Inositol Phosphate Production.** Assays were performed essentially as described previously (Murata et al., 2000). The cells were incubated for 1 min with or without test agents, and the inositol phosphates (sum of inositol bisphosphate and inositol trisphosphate) were measured. The results were normalized to 104 dpm of the total radioactivity incorporated into the cellular inositol lipids, and the radioactivity of trichloroacetic acid (5%)-insoluble fraction was considered as the total radioactivity.

**cAMP Accumulation.** The cells were washed once and preincubated for 10 min at 37°C in HEPES-buffered medium. FRTL-5 thyroid cells were incubated with LPA or other agonists in the presence or absence of Ki6425. Forskolin (10 μM), 100 μM Ro20-1724, and 0.5 units/ml adenosine deaminase were added to the medium. SIP1-, transchol HO cells were similarly incubated with test agents. In this case, the incubation medium contained 10 μM forskolin and 0.5 mM 3-isobutyl-1-methylxanthine. After a 10-min incubation, the reaction was terminated by adding 100 μl of 1 N HCl, and cyclic AMP was measured as described previously (Sho et al., 1991).

**GTPγS Binding.** Binding assay was performed by incubating the membranes with 0.1 nM GTPγS (-2 × 105 dpm/ml) for 30 min at 30°C, as described previously (Im et al., 2000).

**[3H]LPA Binding.** Membrane protein (40 μg) was incubated in 4 ml of the binding buffer (50 mM HEPES, 100 mM NaCl, 5 mM MgCl2, pH 7.5) containing 25 μg/ml of saponin, 0.6 μM BSA, 0.5 μM Na3VO4, 50 μM [3H]LPA (10 Ci/mmol), and different concentrations of Ki6425 and LPA for 60 min at 4°C. The reaction was terminated and binding activity was measured as for GTPγS binding assay. Nonspecific binding was determined in the presence of 10 μM unlabeled LPA.
human LPA3 (GenBank accession number AF127138), according to the previous study (Pages et al., 2001) with slight modifications. The primers for LPA were synthesized according to the cDNA sequence of the human GRP23 (GenBank accession number NM005206). The primers used were: LPA1: forward, 5'-GAACATGGTTGCTAATGCTGCGCAAG-3'; reverse, 5'-TTGCTGGAGCATTCCACGGCAAG-3'; LPA2, forward, 5'-GCTACTCTTCTCCTCAGCTGATCA-3'; reverse, 5'-GGCAGGCTTCTCTCCGTAGCGG-3'; LPA3: forward, 5'-GGCTGAGTTGTTGCAGAGGC-3'; reverse, 5'-CTTTCTCTCCACTATGACAAGC-3'; and TPAP4: forward, 5'-TGAAGGCTTCTCCAAACGTGTCTG-3'; reverse, 5'-GAAGATGTTGCAGAGGCGGAAGGTGAG-3'. The primer sequences in these regions were identical for the human and mouse, except for the reverse primer of mouse LPA2, which was 5'-AGGCTGAGTTGTTGCAGAGGC-3'. Primers for the human orthologs were effective for amplification of mouse (3T3 fibroblasts) and rat (PC-12 cells) LPA3 cDNA. Each PCR was carried out using 2.5 units of Taq DNA polymerase and 1 μl of reverse transcriptase reaction product in a 50-μl reaction mixture containing 20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl2, 200 μM dNTP, and 10 μmol of each primer.

An extended denaturation at 94°C for 4 min was followed by 40 cycles, consisting of denaturation at 94°C for 45 s, annealing at 50°C (LPA1), 50°C (LPA3), 47°C (LPA2), and 52°C (LPA4) for 30 s, and elongation at 72°C for 1 min. After final extension at 72°C for 10 min, the PCR products were analyzed by agarose gel electrophoresis.

**DNA Synthesis.** Swiss 3T3 fibroblasts were pretreated for 10 min with Ki16425 in fresh Dulbecco’s modified Eagle’s medium containing 0.1% BSA and then cultured for 20 h with LPA, S1P, or PDGF, and with [3H]thymidine (0.5 μCi in 1 ml) for another 4 h. The radioactivity in trichloroacetic acid-insoluble fraction was measured as described previously (Kimura et al., 2000).

**Cell Migration.** The migration experiment was performed using a Boyden chamber apparatus (Neuro Probe Inc., Gaithersburg, MD) as described previously (Tamama et al., 2001). Cells remaining on the upper surface of the filters were removed, and the filters were then fixed in methanol and stained with Diff-Quik Solution II (International Reagents Corp., Kobe, Japan). The number of cells that had migrated to the lower surface was determined by counting the cells in four microscopic fields at 400× magnification.

**Calculation of Ks Value.** The Ks values for Ki16425 or DGPP 8:0 were estimated from inositol phosphate responses or Ca2+ responses, based on the following equation: 

\[ K_s = \frac{EC_{50} - B}{EC_{50} - EC_{i0}} \]

where B is the concentration of Ki16425 or DGPP 8:0, and ECi0 and EC50 are the half-maximal effective concentration of LPA in the absence and presence of the antagonist, respectively. The half-maximal effective concentration was estimated as a value that graphically gives a 50% maximal response, unless otherwise specified. With regard to the Schild regressions, the half-maximal effective concentration was estimated from the Scatchard plots. The Ks value was determined by plotting the log of Dose Ratio-1 at each concentration of Ki16425 against the log concentration of Ki16425. The x-intercept of the linear transformation equals the inverse log of the Ks.

**Statistical Analysis.** All experiments were performed in duplicate or triplicate, and the results of multiple observations were presented as means ± S.E. of at least three independent experiments, unless otherwise stated. Statistical significance was assessed by Student’s t test and values were considered significant at p < 0.05.

**Results**

**Pharmacological Characterization of Ki16425.** From 150,000 low-molecular weight compounds screened for selective antagonist action on LPA receptors, Ki16425 was identified as the best candidate (Fig. 1). When we started this study, EDG-family LPA receptors, but not LPA4/GPR23, had been identified. To study pharmacological characteristics of the compound, EDG-family LPA receptor subtypes were transfected into RH7777 cells, which have previously been used as the best candidate (Fig. 1). When we started this study, EDG-family LPA receptors, but not LPA4/GPR23, had been identified. To study pharmacological characteristics of the compound, EDG-family LPA receptor subtypes were transfected into RH7777 cells, which have previously been shown to express none of these LPA receptors in a detectable level (Im et al., 2000). No significant increase in [Ca2+]i increase in inositol phosphate production, or inhibition of calcium accumulation in response to LPA could be found in wild-type or vector-transfected RH7777 cells (data not shown). LPA induced inositol phosphate production in a dose-dependent manner with different efficacy and potency in cells transfected with the different receptor subtypes. In the case of LPA1 and LPA2, 1 μM Ki16425 treatment slightly but significantly suppressed the LPA action, and the inhibitory effect became pronounced at 10 μM. On the other hand, the inhibitory effect of 10 μM Ki16425 in LPA2-expressing cells was marginal, although significant, in the ~0.1-1 μM concentration range of LPA. In all cases, Ki16425 showed a...

![Fig. 2. LPA receptor subtype selectivity of Ki16425. The production of inositol phosphate (IP) by indicated concentrations of LPA was measured in the presence (A, 1 μM; B, 10 μM) or absence (C) of Ki16425 in RH7777 cells expressing LPA1 (A), LPA2 (B), or LPA3 (C). The results are expressed as percentages of the maximal response to 10 μM LPA in the absence of Ki16425. The basal activity and the activity at 10 μM LPA were 553 ± 47 and 1,547 ± 84 dpm for LPA1 cells, 527 ± 43 and 2,590 ± 39 dpm for LPA2 cells, and 743 ± 120 and 2,813 ± 130 dpm for LPA3 cells, respectively. Ki16425 did not significantly change the basal activity. *, the effect of Ki16425 was significant.](image-url)
competitive inhibition pattern, and $K_i$ values were estimated to be 0.34 $\mu$M for LPA$_1$, 6.5 $\mu$M for LPA$_2$, and 0.93 $\mu$M for LPA$_3$, as shown in Table 1. A similar selectivity of Ki16425 was observed to the Ca$^{2+}$ responses in RH7777 cells expressing the different receptor subtypes (data not shown).

To further characterize the actions of Ki16425, we performed GTP$\gamma$S binding assays in membranes prepared from HEK293T cells transfected with cDNAs encoding the LPA receptors and G-protein subunits. In this experiment, we also compared the effects of Ki16425 on the mouse and human orthologs of LPA$_1$. As shown in Fig. 3, LPA receptor transfection introduced an increase in GTP$\gamma$S binding activity in response to LPA. Consistent with a previous study (Im et al., 2000), the potency of LPA was slightly lower for LPA$_3$ than for LPA$_1$ or LPA$_2$. Ki16425 competitively inhibited the LPA-induced action with different potencies, depending on the LPA receptor subtype, and $K_i$ values were calculated from the Schild regressions and presented in Table 1. These values were similar to those estimated from the inositol phosphate responses (Table 1). Ki16425 preferentially inhibited LPA$_1$- and LPA$_3$-mediated responses but had only a moderate effect on LPA$_2$.

**Ki16425 Inhibition Is Selective for LPA Receptors.** To investigate the compound's specificity and usefulness as an antagonist of LPA receptor, we applied Ki16425 to a variety of cell types and measured several cellular responses (Table 2 and Figs. 5–7). The dose-dependent [Ca$^{2+}$], increase elicited by LPA in THP-1 cells (Fig. 5A) and in 3T3 fibroblasts (Fig. 5B) was inhibited by Ki16425 in a competitive manner: the $K_i$ value was estimated to be 0.17 $\mu$M in THP-1 and 0.54 $\mu$M in 3T3 fibroblasts. Likewise, in A431 cells, the LPA response was markedly inhibited by Ki16425 (Table 2). Thus, Ki16425 is a potent and reversible antagonist (Fig. 5C).
this experiment, 3T3 fibroblasts were incubated with or without 10 μM Ki16425 for the last 1 or 10 min during labeling time with Fura2/AM, the cells were washed with fresh medium three times, and the Ca\(^{2+}\) response to LPA was measured.

Fig. 4. Effect of Ki16425 on LPA receptor binding. A, effect of receptor transfection on the LPA-specific binding. The same HEK293T cell membranes as those in Fig. 3 were used. The membranes from the cells that were transfected with mLPA\(_1\) or hLPA\(_2\) were incubated with 5 nM \(^{[3H]}\)LPA. LPA-specific binding without (control) or with 10 μM Ki16425 was measured by subtracting the nonspecific binding activity (6,000 dpm); this value remained unchanged by receptor transfection. The specific binding was increased by the transfection of LPA\(_1\) or LPA\(_2\) (Fig. 4A) but not by the transfection of LPA\(_3\), possibly because of the lower potency of LPA in LPA\(_3\)-expressing cell membranes. The results are shown as LPA specific binding ± S.E. B, the increase in the binding activity caused by receptor transfection was attributed to an LPA receptor-dependent binding activity, and the effect of Ki16425 is expressed as a percentage of this activity. From the LPA receptor binding data, the \(K_i\) value can be theoretically estimated from the following equation: \(K_i = (IC_{50} \times K/K + A)\), where \(A\) is the concentration of \(^{[3H]}\)LPA used for the binding experiment (5 nM), \(IC_{50}\) is the half-maximal inhibitory concentration of Ki16425 (0.72 μM for LPA\(_1\) and 22 μM for LPA\(_2\), estimated from Fig. 4B), and \(K\) is the dissociation constant of LPA for the receptor. However, an accurate \(K\) value could not be determined (see text). Instead, we used an \(EC_{50}\) value of LPA for GTP\(\gamma\)S binding (72 nM for LPA\(_1\) and 148 nM for LPA\(_2\), estimated from Fig. 3) as the \(K\) value and \(K_i\) values were estimated to be 0.67 and 21.3 μM for mouse LPA\(_1\) and human LPA\(_2\), respectively. * the effect of Ki16425 was significant in A and the activity was significant between LPA\(_1\) and LPA\(_2\) in B.

Fig. 5. Effect of Ki16425 on \([Ca^{2+}]_i\) increase induced by LPA in THP-1 cells and 3T3 fibroblasts. Ca\(^{2+}\) response to indicated concentrations of LPA was measured in the presence (●) or absence (○) of Ki16425 (1 μM) in THP-1 cells in (A) and Swiss 3T3 fibroblasts (B). The results are expressed as percentages of the maximal \([Ca^{2+}]_i\) increase (404 ± 27 nM in THP-1 cells and 1,256 ± 87 nM in Swiss 3T3 fibroblasts) by 100 μM LPA in the absence of Ki16425. Inset, Ca\(^{2+}\) response to 100 nM LPA was measured in the presence of indicated concentrations of Ki16425. The results are expressed as percentages of the \([Ca^{2+}]_i\) increase (217 ± 36 nM in THP-1 cells and 759 ± 73 nM in Swiss 3T3 fibroblasts) by 100 μM LPA in the absence of Ki16425. C, the reversibility of the Ki16425 effect was examined in Swiss 3T3 fibroblasts. The cells were incubated for 1 or 10 min with or without 10 μM Ki16425 during labeling time with Fura 2/AM and washed three times with the HEPES-buffered medium. The \([Ca^{2+}]_i\) increase by 100 nM LPA was then examined after the 1- or 10-min preincubation with or without 10 μM Ki16425.
sured in the presence or absence of Ki16425. There was no significant effect of the pretreatment with Ki16425 on the LPA action, indicating that the compound could be washed out without leaving residual inhibition.

In PC-12 cells, Ki16425 had only a small, although significant, inhibitory effect on the Ca^{2+} response to LPA. In HL-60 cells, a small but significant [Ca^{2+}], increase by LPA was insensitive to Ki16425 (Table 2). Thus, Ki16425 inhibited the LPA-induced Ca^{2+} response in THP-1 cells, 3T3 fibroblasts, and A431 cells, but had only a marginal effect in PC-12 cells and HL-60 cells. On the other hand, the Ca^{2+}

responses to ATP, PAF, and SPC in THP-1 cells, PDGF and S1P in 3T3 fibroblasts, EGF and PAF in A431 cells, and SPC, lysophosphatidylcholine, psychosine, and 2-arachidonoylglycerol in HL-60 cells were not significantly inhibited by Ki16425 (Table 2).

Figure 6 shows the effect of Ki16425 on the inositol phosphate response. This LPA-induced response in 3T3 fibroblasts (Fig. 6A) and A431 cells (Fig. 6C) was inhibited by Ki16425, and the mode of Ki16425 inhibition was consistent with competitive inhibition in 3T3 fibroblasts (the \( K_i \) value was 0.68 \( \mu M \)). In contrast, the responses to S1P in 3T3 fibroblasts (Fig. 6A, right), S1P_{3}-expressing CHO cells, and S1P_{2}-expressing CHO cells (Fig. 6B) were insensitive to Ki16425. Similarly, the response to PAF and bradykinin was not significantly affected by the inhibitor (Fig. 6C).

Figure 7 shows the effects of Ki16425 on the inhibition of the forskolin-induced cAMP accumulation in response to LPA and phenylisopropyladenosine, an A_{1} adenosine receptor agonist, and S1P. LPA inhibited cAMP accumulation in FRTL-5 thyroid cells in a PTX-sensitive manner (Fig. 7A), suggesting a G_{i}-mediated inhibition of the LPA action. This inhibition by LPA was significantly suppressed by Ki16425 even at 0.1 \( \mu M \) and almost completely at 10 \( \mu M \). However, the phenylisopropyladenosine-induced inhibition was insensitive to even 10 \( \mu M \) Ki16425, although the inhibition was PTX-sensitive in the same cells (Fig. 7B), thus ruling out the possibility that Ki16425 might act on G_{i}-proteins. Likewise, the inhibition of cAMP accumulation by S1P in S1P_{1}-expressing CHO cells was hardly affected by Ki16425 (Fig. 7C), and

Fig. 6. Effects of Ki16425 on inositol phosphate production. Inositol phosphate response to indicated concentrations of agents was measured in 3T3 fibroblasts (A), S1P_{3}- or S1P_{2}-expressing CHO cells (B) in the presence (O) or absence (C) of Ki16425 (10 \( \mu M \)). A, results are expressed as percentages of the respective maximal response to 10 \( \mu M \) LPA or S1P in the absence of Ki16425. The maximal response was obtained by subtracting the basal activity (1,245 \pm 127 dpm) from the maximal activity (2,258 \pm 240 dpm by 10 \( \mu M \) LPA and 2,901 \pm 100 dpm by 10 \( \mu M \) S1P). B, the maximal response was evaluated in a manner similar to that described in A; the activity was changed from 678 \pm 57 to 4,206 \pm 214 dpm by 1 \( \mu M \) S1P (left) and from 631 \pm 16 to 1,382 \pm 10 dpm by 10 \( \mu M \) S1P (right). C, inositol phosphate response to indicated concentrations of LPA, PAF, or bradykinin (BK) in the presence or absence of Ki16425 (1–10 \( \mu M \)) was measured in A431 cells. Results are expressed as the net increase in the activity by the respective agent. The basal value without agonist was 1,093 \pm 12 dpm and was not appreciably changed by Ki16425 treatment.

Fig. 7. Effect of Ki16425 on cAMP response. FRTL-5 cells (A and B), treated or not treated with PTX, or S1P_{1}-expressing CHO cells (C) were incubated with indicated concentrations of LPA, phenylisopropyladenosine (PIA), or S1P in the presence or absence of Ki16425. The results are expressed as percentages of the value obtained without these agonists. These values were 41.6 \pm 3.6 nmol/10 mg of protein for FRTL-5 cells and 6.36 \pm 0.38 nmol/10 mg of protein for S1P_{1}/CHO cells. These values were not appreciably affected by PTX or Ki16425 treatment.
this S1P action was also reversed by PTX treatment (data not shown).

In summary, Ki16425 was found to specifically inhibit LPA-induced response without any appreciable effect on responses to other receptor agonists. However, the extent of the LPA-induced inhibition seemed to depend on the cell types; the inhibition was marginal in PC-12 cells and undetectable in HL-60 cells.

**Differential Expression of LPA Receptor Subtypes May Explain the Susceptibility to Ki16425.** mRNA expression of LPA receptor subtypes in the cells used (Figs. 5–7) was examined by Northern blotting and RT-PCR methods. Some of the results are summarized in Table 2. As seen in Fig. 8, A431 cells express all subtypes of EDG-family LPA receptor mRNAs but not LPA4/GPR23 mRNA; 3T3 fibroblasts and THP-1 cells express LPA1, LPA2, and LPA3 mRNAs; HL-60 cells express LPA2 and LPA4 mRNAs; FRTL-5 cells express LPA1 mRNA as a major band; and PC-12 cells express LPA2 mRNA as a major band. Although the size of LPA2 mRNA differed among the cell types, as shown by Northern blotting (Fig. 8A), a single band with a similar size was amplified by RT-PCR (Fig. 8B). This suggests the heterogeneity of LPA2 mRNA, possibly because of alternative splicing (An et al., 1998a,b). In the case of LPA3, a trace band with almost the same size as the band in A431 cells was detected in HL-60 and THP-1 cells by Northern blotting (Fig. 8A); however, no specific band was amplified by RT-PCR. Thus, the expression of LPA3 mRNA in HL-60 and THP-1 cells could not be confirmed. LPA1 mRNA was detected in Ki16425-sensitive A431 cells, FRTL-5 cells, 3T3 fibroblasts, and THP-1 cells. On the other hand, LPA2 and/or LPA4 were detected in Ki16425-insensitive or less-sensitive HL-60 cells.

**Fig. 8.** Northern blot (A) and RT-PCR (B) analyses of LPA receptor mRNAs in various cell types. As a positive control for LPA4/GPR23, rat ovary was used. It should be noted that even though the size of LPA2 mRNA determined by Northern blotting differed among cell types, a single band with a similar size was amplified by RT-PCR analysis for LPA2.

**Fig. 9.** Effects of Ki16425 on DNA synthesis and migration of Swiss 3T3 fibroblasts. A, the cells were incubated with indicated concentrations of agonists in the presence or absence of Ki16425 (1 μM). The net increase in thymidine incorporation by the respective agonist is shown. The basal activity without agonists was 89,000 ± 1,500 dpm in the absence of Ki16425 and 60,000 ± 8,000 dpm in the presence of 1 μM Ki16425. B, the cells were incubated with 10 μM LPA, 10 μM S1P, or 400 μM PDGF in the presence of the indicated concentration of Ki16425. The results are expressed as percentages of the net activity induced by the respective agonist as shown in A. C and D, the cells were treated with the indicated concentrations of Ki16425 and loaded into the upper wells of the Boyden chamber, and then cell migration for 4 h was measured. The lower wells were filled with the indicated concentrations of LPA or PDGF. The number of cells that migrated into the lower surface of the membrane filter was counted.
and PC-12 cells as major bands (Fig. 8 and Table 2). Thus, cell sensitivity to Ki16425 seems to reflect the differential expression of LPA receptor subtypes, especially LPA1, and Ki16425 seems to be a useful tool for evaluating the involvement of specific LPA receptors in the short-term response to LPA.

**Ki16425 Inhibits Long-Term DNA Synthesis and Cell Migration As Induced by LPA.** We next examined whether Ki16425 was applicable for inhibiting long-term responses including DNA synthesis (24 h) and cell migration (4 h). As shown in Fig. 9A, the LPA-induced DNA synthesis in 3T3 fibroblasts was markedly inhibited by 1 μM Ki16425, but those induced by S1P and PDGF were not appreciably affected at this concentration of the compound. Significant inhibition of the LPA-induced action by Ki16425 was observed at ~0.01 to 0.1 μM, but DNA synthesis induced by S1P or PDGF was not affected even at 3 μM (Fig. 9B). LPA maximally stimulated the migration of 3T3 fibroblasts at 100 nM, and the activity declined as the LPA concentration increased. The bell-shaped migration response to LPA was also observed in glioma cells (Manning et al., 2000) and lymphocytes (Zheng et al., 2001), although the mechanism has not yet been well characterized. One possible mechanism might be desensitization caused by high agonist concentration. Ki16425 at ~0.1 to 1 μM significantly inhibited the peak migration activity (Fig. 9C), but PDGF-induced cell migration was not inhibited under these conditions (Fig. 9D), similar to the case of DNA synthesis (Fig. 9B).

**Evaluation of LPA Receptor Subtypes Involved in LPA-Induced Actions.** DGPP 8:0 has recently been re...

---

**Fig. 10.** Subtype selectivity of DGPP 8:0 on LPA receptors. LPA1 (A), LPA2 (B), or LPA3 (C) -RH7777 cells were incubated with the indicated concentrations of LPA in the presence (●) or absence (○) of 30 μM DGPP 8:0. The results are expressed as the percentages of the value obtained at 10 μM LPA in the absence of Ki16425. The 100% values were 511 ± 4 nM for LPA1-expressing cells, 688 ± 40 nM for LPA2-expressing cells, and 908 ± 38 nM for LPA3-expressing cells.

**Fig. 11.** Evaluation of the subtype of LPA receptors involved in inositol phosphate response in A431 cells. A, the effect of PTX on the LPA-induced action. Normal A431 cells not treated with PTX or A431 cells treated with the toxin were incubated with the indicated concentrations of LPA. The results are expressed as percentages of the response at 10 μM LPA in the normal or PTX-treated cells shown in A. B, normal cells; C, PTX-treated cells. The LPA-induced activity was measured in the absence or presence of 1 μM Ki16425, 10 μM Ki16425, or 30 μM DGPP 8:0. The results are expressed as percentages of the response at 10 μM LPA in the normal or PTX-treated cells shown in A.
ported as a selective antagonist of LPA₁ and LPA₃ (Fischer et al., 2001). Therefore, we attempted to confirm the pharmacological specificity of DGPP 8:0 for LPA receptor subtypes. As shown in Fig. 10, this compound clearly inhibited the LPA₁-mediated Ca²⁺ response and slightly but significantly inhibited the LPA₃-mediated one. The competitive inhibition by DGPP 8:0 was also observed for the inositol phosphate response in LPA₁-expressing CHO cells (data not shown). However, as originally proposed (Fischer et al., 2001), this agent was ineffective for the LPA₂-mediated Ca²⁺ response (Fig. 10B) and the inositol phosphate response (data not shown). Based on the ability to inhibit Ca²⁺ response, the Kᵢ values of DGPP 8:0 were estimated to be 19.9 μM for LPA₁ and 3.33 μM for LPA₃. Thus, DGPP 8:0 was more effective for LPA₃ than LPA₁, whereas Ki16425 was slightly more effective for LPA₁ than LPA₃ (Table 1).

Finally, we explored the differences in the receptor selectivity of DGPP 8:0 and Ki16425 for the evaluation of the lipid receptor subtypes involved in the LPA response in A431 cells. A431 cells express three EDG-family LPA receptor subtypes but not LPA₄ (Fig. 8 and Table 2). As shown in Fig. 11A, LPA induced inositol phosphate production in a dose-dependent manner and was partially inhibited by PTX. When the effects of Ki16425 were compared in A431 cells (Fig. 11B) and PTX-treated cells (Fig. 11C), 1 μM Ki16425 was inhibitory at the lower concentrations (~10–100 nM) of LPA in normal cells; the Kᵢ value was 0.73 μM, which is comparable with that of the mean for LPA₁ or LPA₃ (Table 1). However, DGPP 8:0 was found to be ineffective (Fig. 11B, right). These results suggest that the LPA-induced inositol phosphate response is predominantly mediated by LPA₁ in normal A431 cells. On the other hand, in the PTX-treated A431 cells, Ki16425, even at 10 μM, hardly affected the LPA-induced action (Fig. 11C), suggesting that LPA₂, but neither LPA₁ nor LPA₃, might be a major receptor subtype in the PTX-treated A431 cells. Thus, in normal A431 cells, both LPA₁ as a major route and LPA₂ as a minor route may mediate the LPA-induced inositol phosphate response.

**Discussion**

In the present study, we showed that Ki16425 inhibited LPA-induced actions, including short-term (~10 min) (i.e., Ca²⁺, inositol phosphate response, and cAMP responses) and long-term responses (~4–24 h) (i.e., DNA synthesis and cell migration). Ki16425 did not exhibit any significant effects on the other receptor agonist-induced actions, including S1P, SPC, psychosine, 2-arachidonoylglycerol, PAF, lysophosphatidylcholine, ATP, A₁-adenosine receptor agonist, bradykinin, EGF, and PDGF. Among the EDG-family LPA receptor subtypes analyzed in the present study, Ki16425 preferentially inhibited LPA₁- and LPA₃-mediated actions but only weakly inhibited those mediated by LPA₂. Because GPR23 was reported as a fourth LPA receptor during the review process of this article, it remains to be elucidated whether Ki16425 affects LPA₂/GPR23. The inhibition of the LPA-induced actions by Ki16425 showed a competitive pattern; Ki16425 least inhibited LPA binding to LPA₁, but with a high potency, whereas to LPA₂, it was inhibitory with a low potency, suggesting a competitive antagonist for LPA receptors with a preference for LPA₁ and LPA₃ over LPA₂.

Recent studies suggest that ligands loosely classified as antagonists can be divided into at least two classes: neutral antagonists, which possess no intrinsic activity, and inverse agonists, which possess negative intrinsic activity (de Ligt et al., 2000). Thus, inverse agonists can inhibit the basal activity without agonist stimulation. Ki16425 inhibited the basal activity of GTP·S binding (Fig. 3), suggesting that Ki16425 might be an inverse agonist. The basal activity in the inositol phosphate assay, however, was not changed by Ki16425 (Fig. 2). It remains to be elucidated whether the discrepancy of the results is caused by the differences in the time employed in these assays (i.e., 30 min in the GTP·S binding assay and 1 min in the inositol phosphate assay). Increasing the incubation time of inositol phosphate assay and the effects of other LPA receptor antagonists (mentioned below) on the Ki16425-induced GTP·S binding may help to conclude that Ki16425 is a neutral antagonist or an inverse agonist.

Recently, several agents have been shown to inhibit LPA-induced actions, although their effects on LPA binding have not yet been reported. DGPP 8:0 has been shown to have a preferential competitive property for LPA₃ over LPA₁ and was ineffective on LPA₂ (Fischer et al., 2001). Consistent with this, we also observed in the present study that this agent competitively inhibited the LPA-induced Ca²⁺ response; the Kᵢ value was estimated to be 3.33 μM for LPA₃ and 19.9 μM for LPA₁, but no inhibitory effect was detected for LPA₂. Based on the GTP·S binding assay in HEK293 cells (Heise et al., 2001), VPC12249 has been shown to exert a selective and competitive inhibitory effect on LPA₁ (Kᵢ value of 0.14 μM) and LPA₃ (Kᵢ value of 0.43 μM), but not on LPA₂. Thus, DGPP 8:0 is selective for LPA₃, whereas VPC12249 is selective for LPA₁ and LPA₃. Ki16425 seems to have a pharmacological specificity similar to that of VPC12249, but the effect of the former on LPA₂ is not negligible. Thus, Ki16425 has a broad selectivity on LPA receptor subtypes compared with the previously described LPA antagonists, although its interaction on the recently identified LPA₄ remains uncharacterized. Such a broad selectivity might be beneficial to the evaluation of the participation of LPA in the biological responses compared with strictly subtype-selective LPA antagonists.

The differential subtype selectivity of Ki16425 and DGPP 8:0 was successfully applied for the evaluation of the LPA receptor subtypes involved in biological responses. In the present study, we analyzed in detail the inositol phosphate response to LPA in A431 cells, which seem to express all three EDG-family LPA receptor subtypes but not LPA₄ (Fig. 8). The LPA-induced action was sensitive to Ki16425 in normal cells (Fig. 11B) but insensitive to the antagonist in the PTX-treated cells (Fig. 11C). The change of susceptibility to Ki16425 may be explained as follows. In normal A431 cells, both LPA₁ and LPA₂ may couple to G₁ and Gᵢ, respectively, thereby mediating the LPA-induced inositol phosphate response; however, the minor LPA₂/Gᵢ pathway may be masked by the major LPA₁/G₁ pathway. When G₁ was inactivated by PTX, however, the LPA₂/Gᵢ pathway was unmasked as a major route for the activation of phospholipase C. The Ca²⁺ and inositol phosphate responses to LPA in THP-1 cells and 3T3 fibroblasts seem to be mediated mainly by LPA₁, as evidenced by their susceptibility to Ki16425 (Fig. 5) but not to DGPP 8:0 (data not shown). Although the effect of Ki16425 on LPA₄ has not yet been examined, LPA₄ might be insensitive to Ki16425, because the Ca²⁺ response to LPA
in LPA$_1$-expressing HL-60 cells was barely affected by Ki16425 (Table 2). The slight difference in the $K_i$ value between THP-1 cells (0.17 $\mu$M for Ca$^{2+}$ response) and 3T3 cells (0.54 $\mu$M for the Ca$^{2+}$ response and 0.68 $\mu$M for the inositol phosphate response) might reflect the difference in the contribution of LPA$_2$ or LPA$_3$ to these responses. Concerning the inhibition of the cAMP response in FRTL-5 cells, it is likely that LPA$_1$ is the major receptor subtype in this cell line. First, LPA$_1$-induced inhibition of cAMP accumulation was sensitive to Ki16425 (Fig. 7A), but not to DGPP 8:0 (data not shown). Second, only LPA$_1$ among the subtypes was effective for inhibiting cAMP accumulation when transfected (Im et al., 2000; Noguchi et al., 2003). Finally, only LPA$_1$ mRNA was detected in FRTL-5 cells (Fig. 8). Thus, these antagonists are potentially useful for discerning receptor subtypes involved in the given response, even when more than one LPA receptor subtype is expressed.

Ki16425 was also effective in the long-term responses, including DNA synthesis and cell migration in Swiss 3T3 fibroblasts (Fig. 9). Although LPA$_1$-induced DNA synthesis is one of the well known actions of the lipid mediator, its mechanism has not been fully characterized. In NIH 3T3 cells and other cell types, LPA$_1$-induced DNA synthesis seems to be mediated through a tyrosine phosphorylation of EGF receptors (Daub et al., 1997; Cunnick et al., 1998). Thus, it is possible that Ki16425 inhibited the LPA$_1$-induced action by interacting with the EGF receptor. This mechanism is unlikely, however, because EGF was not a significant stimulator for DNA synthesis in Swiss 3T3 fibroblasts (data not shown), and EGFr-mediated Ca$^{2+}$ response was not affected by Ki16425 in A431 cells (Table 2). In any event, Ki16425 maintained its specific property for a long period (24 h), suggesting again that Ki16425 is a useful agent to evaluate the role of LPA$_1$ and its receptors in long-term as well as short-term responses.

In conclusion, Ki16425 selectively inhibited the EDG-family LPA receptor-mediated actions with preference to LPA$_1$ and LPA$_3$ in vitro. This compound might also potentially serve as a therapeutic drug for diseases that involve LPA and its receptors in their initiation or progression (e.g., atherosclerosis and cancer).

Acknowledgments

We are grateful to Prof. Kevin R. Lynch of University of Virginia School of Medicine for the generous gift of mouse LPA$_1$ cDNA and LPA$_1$-expressing RH7777 cells, to Prof. Sang-Duk Kim of Korea University for critically reading the manuscript, and to Masayo Yanagita and Mayumi Komachi for technical assistance.

References


**Address correspondence to:** Fumikazu Okajima, Ph.D., Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, 3-39-15 Showa-machi, Maebashi 371-8512, Japan. E-mail: fokajima@showa.gunma-u.ac.jp